Prior studies suggest that depletion of CD8 þ T cells from donor bone marrow or donor lymphocyte infusions can reduce graft-versus-host disease (GVHD) without compromising graft-versus-leukemia. We explored CD8 depletion in patients undergoing matched related donor (MRD, n ¼ 25) and unrelated donor (URD, n ¼ 16) peripheral blood stem cell transplantation following myeloablative conditioning with cyclophosphamide (60 mg/kg/ day i.v. Â 2) and total body irradiation (200 cGy Â 7 fractions). Ex vivo incubation of mobilized donor peripheral blood cells with anti-CD8 antibody coated high-density microparticles removed 99% of CD8 þ cells. The median number of CD8 þ cells infused was 3.9 Â 10 5 cells/kg (2.2 Â 10 5 in MRD, and 8.1 Â 10 5 in URD patients). Post transplant immune suppression included tacrolimus in the MRD cohort, and tacrolimus plus mini-methotrexate (5 mg/m 2 days þ 1, 3, 6, 11) in the URD cohort. All 41 patients engrafted. Grade 2-4 acute GVHD incidence was 61% (44% MRD, 88% URD). Chronic GVHD incidence was 50% (48% MRD, 55% URD). Relapse incidence was 4.9%. Estimated event-free and overall survival rates were 65 and 63%, respectively, at 1 year and 56 and 57%, respectively, at 2 years. There was no correlation between CD8 þ number and GVHD or survival. A 2-log depletion of CD8 þ cells from PBSC is insufficient to prevent GVHD.
poietic cell transplantation (HCT). 1 However, most TCD techniques have led to loss of graft-versus-leukemia (GVL) activity, and many have been associated with graft failure, delayed immunologic recovery, and the development of post transplant lymphoproliferative disease (PTLD). [1] [2] [3] [4] [5] [6] [7] Consequently, the use of TCD has not improved overall survival after transplant.
The extent and specificity of TCD may influence its effect on relapse rates as well as engraftment. In a large retrospective International Bone Marrow Transplant Registry (IBMTR) analysis, TCD with 'narrow specificity' antibodies was associated with a lower relapse rate and better survival than TCD with 'broad specificity' antibodies. 8 It would be ideal if cellular subsets that mediate GVL and GVH could be distinguished so that those cells that cause GVHD could be removed from the graft, leaving intact the population responsible for GVL activity.
Precisely which T cell subset to target for depletion remains uncertain. However, there is accumulating evidence that suggests a partial reduction of CD8 þ T cells can reduce GVHD without compromising GVL. The potential to separate GVL from GVHD through depletion of CD8 þ T cells has been supported by recent studies of donor lymphocyte infusions (DLI). CD8 þ depleted DLI retains GVL activity with preserved clinical responses in patients with recurrent CML after transplantation. 9, 10 A randomized study of CD8 þ TCD in patients receiving DLI demonstrated a reduction in acute GVHD from 66 to 0% without loss of GVL activity.
11 CD8 þ TCD of donor bone marrow as primary GVHD prophylaxis has been tested in a randomized trial, and indeed resulted in reduced rates of grades acute 2-4 GVHD without any increase in leukemia relapse. 12 However, in that trial which utilized bone marrow, survival was not improved because of increased rates of graft failure and infectious complications.
The emergence of mobilized peripheral blood stem cells (PBSC) as an alternative to bone marrow provides an opportunity to re-evaluate CD8 þ TCD as a form of primary GVHD prophylaxis. [13] [14] [15] We hypothesized that, despite CD8 þ TCD, the greater number of CD34 þ cells and memory T cells in mobilized peripheral blood would facilitate engraftment and allow more rapid immunologic recovery -particularly of CD4 þ T cells, while maintaining GVL activity. Modulation of allo-reactivity is particularly relevant for peripheral blood transplantation since it is associated with increased rates of chronic GVHD. 15, 16 We designed a trial to assess the feasibility of CD8 depletion of mobilized peripheral blood cells and determine the effect of this engineering process on engraftment as well as on GVHD, immune reconstitution, and relapse.
Methods

Patients
Between September 2001 and July 2003, 41 patients were enrolled in two clinical trials (DFCI protocol 01-089 for related donor transplantation and 02-113 for unrelated donor (URD) transplantation). The Human Subjects Protection Committee at the Dana-Farber Cancer Institute/Harvard Cancer Center approved the protocols, and all subjects provided informed consent according to the Declaration of Helsinki. The matched related donor (MRD) trial was initiated in September 2001, and based on encouraging survival data, the URD trial was launched in September 2002. All donor-recipient pairs were HLA matched at HLA-A, B, and DRB1. HLA class I typing was based on complement dependent cytotoxicity assay. Matching at HLA class II was performed by PCR of sequence-specific primers (SSP). Eligibility for enrollment included ECOG performance status 0-2, serum creatinine and bilirubin levels less than two times the upper limit of normal, and the absence of active infection.
Diagnoses included acute myelogenous or lymphoblastic leukemia, chronic myelogenous or lymphocytic leukemia, myelodysplastic syndrome, and non-Hodgkin's lymphoma.
Donors and stem cell mobilization
HLA MRDs were treated with filgrastim at 10 mg/kg/day subcutaneously for 5 days. On the fifth day, the donor underwent leukapheresis with a target of 5 Â 10 6 CD34 þ cells/kg recipient weight. The donor was leukapheresed 1 or 2 days to achieve that target. If that could not be achieved in 2 days, then a minimum of 2 Â 10 6 CD34 þ cells/kg recipient weight was considered acceptable. Filgrastim mobilized PBSC from URDs were collected according to standard procedure from the originating center, and was delivered fresh to our center for processing.
CD8 depletion of mobilized PBSC
The CD8-HDM (high-density microparticles, BB-IDE 6969, BioTransplant, Inc., Charlestown, MA, USA) device depletes blood products of CD8 þ cells. The device consists of a murine IgG anti-CD8 monoclonal antibody coated onto dense nickel particles. Apheresis PBSC products from filgrastim mobilized normal donors were processed using the T-Cell-HDM Cell Separation System in accordance with the manufacturer's instructions. In brief, a set of three vials, each containing 10 ml of CD8-HDM, was provided in the device kit to be utilized for each sample. Contents of each vial were extracted and transferred into separate 175 ml HDM depletion chambers. The donor apheresis product was added to the first HDM depletion chamber, mixed, and then allowed to sediment by gravity for 10 min. The CD8 þ cell-depleted supernatant was transferred into the second HDM depletion chamber, and this process was repeated in the second and third HDM depletion chambers. The CD8-depleted product was resuspended in autologous plasma. Samples of the apheresis product were removed prior to processing with CD8-HDM and after completion of the CD8 þ cell depletion. These samples were used to enumerate the viability and total number of CD4 þ and CD8 þ cells. Postdepletion samples were also tested for residual CD8 monoclonal antibody and nickel levels.
Treatment program
The conditioning regimen consisted of cyclophosphamide (60 mg/kg per day i.v. Â 2) and total body irradiation (1400 cGy divided into seven fractions over 4 days). CD8 þ depleted mobilized peripheral blood cells were infused on the last day of TBI. If a second day of collection was required from the donor, patients received stem cells on two consecutive days. Patients received filgrastim (5 mg/kg starting day þ 1) after stem cell infusion until engraftment. In the MRD cohort, additional GVHD prophylaxis consisted of tacrolimus alone, which was administered at a starting dose of 0.02 mg/kg/day i.v. continuous infusion beginning at day -3 to achieve a target level of 5-10 ng/ml. In the URD cohort, additional GVHD prophylaxis consisted of tacrolimus starting at day -3 as above, plus methotrexate 5 mg/m 2 on days þ 1, 3, 6, 11. Prophylactic oral levofloxacin was administered until patients developed neutropenic fever, at which point intravenous antibiotics were initiated. Routine clinical care included pneumocystis carinii prophylaxis with trimethoprim-sulfamethoxazole or atovaquone beginning by day þ 30, and continued for 1 year and varicella zoster prophylaxis with acyclovir beginning on admission and continuing for 1 year. Antifungal prophylaxis was not routinely given. CMV surveillance was conducted through at least day þ 120 by weekly assessment of viral load with a hybrid capture assay. CMV reactivation was treated with either ganciclovir or valganciclovir. Intravenous gammaglobulin replacement was not routinely given as infection prophylaxis, but was allowed at the discretion of the treating physician for patients who developed hypogammaglobulinemia post transplant.
Immunophenotypic analysis
Expression of CD3, CD4, CD8, CD20, CD25, CD56, CD45 RO and CD45 RA on fresh peripheral blood mononuclear cells (PBMC) was determined by incubating aliquots of 0.5 to 1 Â 10 6 cells in the presence of the respective mAb at 41C for 30 min. After washing, the cells were fixed with 1% paraformaldehyde in PBS and flow cytometry analysis was performed. Immunophenotyping of the stained and fixed cells was performed on a Coulter Cytomics FC500 flow cytometer (Beckman Coulter, Fullerton, CA, USA). All monoclonal antibodies were pretitered on normal PBMC to determine their optimal dilutions.
Chimerism analysis
Recipients and donors were genotyped at nine short tandem repeat (STR) loci (D3S1358, FGA, VWA, D8S1179, D21S11, D18S51, D5S818, D13S317, D7S280) and the Amelogenin locus. The genotyping was performed using Applied Biosystem's PCR based AmFlSTR Profiler Plus kit and a 310 Genetic Analyzer, which permits identification of alleles and quantification of the DNA template attributable to those alleles. Informative loci were identified by the presence of alleles that were unique to recipient or donor. DNA was extracted from nucleated cells from post transplant recipient peripheral blood and bone marrow aspirate samples. Percent donor chimerism was calculated at each informative locus as 100 Calculations are automated using an in-house Chimeratron software package.
Biostatistical considerations
Both MRD and URD trials were similarly designed so that the primary end point was graft failure determined on or before 30 days after PBSC infusion. Both studies had a two-stage design. Initially, 10 patients were to be entered on study. If no more than one of the 10 patients experienced graft failure, an additional 15 patients were enrolled. If no more than two cases among the 25 patients experienced graft failure, this treatment strategy was to be considered of interest. The URD trial was terminated early due to a high incidence of acute GVHD.
Descriptive statistical analysis was performed to assess patient baseline characteristics, disease, disease stage, GVHD, CD8 and CD4 cell counts and chimerism data. The two-sided Wilcoxon-Rank-Sum test was used for the comparison of numbers of CD8 and CD4 cells infused between grade 0-1 and grade 2-4 acute GVHD. Cumulative incidence curve for acute GVHD was constructed reflecting time to onset of acute GVHD and time to early death without acute GVHD as competing risks. 17 Overall survival and event-free survival were calculated using the Kaplan-Meier method. 18 Event-free survival was defined as the time from stem cell infusion to relapse or death from any cause. Patients who were alive without relapse were censored at the time last seen alive and relapse-free. The Cox proportional hazards model and logistic regression model were used to examine association between the number of CD8 þ cells infused and survival, and the number of CD8 þ cells infused and acute GVHD, respectively.
Results
Patient characteristics
Patient characteristics are summarized in Table 1 . The combined MRD and URD cohort consisted of 24 males and 17 females, with a median age of 43 years (range, 24-57 years). Diseases included AML (16), NHL (6), MDS (6), ALL (5), CML (6), CLL (2). In total, 27 (66%) were classified as having advanced disease, defined as any condition other than CML first chronic phase, acute leukemia in first remission, or myelodysplasia with refractory anemia or refractory anemia-ringed sideroblasts. There were 14 gender mismatched donor-recipient pairs (nine M-F, five F-M). Among the 16 unrelated CD8 þ T-cell-depleted allogeneic PBSCT VT Ho et al transplant recipients, three had donors who were antigen mismatched at HLA-C.
Composition of the stem cell product Table 2 describes the composition of the donor cell products after processing. The median number of CD34 þ cells after processing was 5.96 Â 10 6 CD34 þ cells/kg (range,
5 cells/kg (range, 1.7-50.6) in the URD cohort, corresponding to an average depletion of 2 logs or 99.0% (range, 86-100%). The difference in CD8 þ content between the MRD and URD grafts was statistically significant (P ¼ 0.001). This difference was attributable to the difference in the initial number of CD8 þ cells in the products rather than the efficacy of the depletion process. The variability in lymphocyte content in PBSC products from related vs URDs may reflect differences in practice among donor centers, such as dose and/or schedule of G-CSF used for stimulation, and/or parameters specific to leukapheresis devices.
Engraftment
All 41 patients engrafted. An absolute neutrophil count of 500/ml was achieved at a median of day þ 11 (range, 9-15). Sustained platelet counts 420 000/ml were attained at a median of day þ 16 (range, ). There were no cases of late graft failure in either group. Chimerism studies of bone marrow and unfractionated leukocytes revealed 499% donor cells in peripheral blood in all patients tested 3-6 months post transplant. Donor hematopoiesis was maintained at this level in all but one patient who demonstrated recipient cells at the time of relapse.
Acute GVHD
The incidence of acute GVHD is presented in Table 3 , and the cumulative incidence of grade 2-4 acute GVHD is shown in Figure 1 . In total, 25 of 41 patients (61%) developed grade 2-4 acute GVHD, 11 (44%) in the MRD cohort, and 14 (88%) in the URD cohort. The combined incidence of grade 3-4 acute GVHD was 11/41 (27%). In a logistic regression model including age, donor type, patient gender, disease, and disease stage at transplant, no association between grade 2-4 acute GVHD and the number of CD8 þ cells infused was detected. In total, 16 of the 25 patients scored as having GVHD (64%) experienced a syndrome with erythematous rash and high fevers developing at or just prior to the time of neutrophil recovery. These patients were treated with steroids with prompt improvement. Despite the rapid resolution of fever and skin rash after initiation of steroids (1-2 mg/kg/day methylprednisolone), we could not be certain that this phenomenon was not hyperacute GVHD, and we adopted Table 2 Stem cell product composition pre-and postprocessing with CD8-HDM CD8 þ T-cell-depleted allogeneic PBSCT VT Ho et al a policy of tapering the steroids weekly according to our standard guidelines for acute GVHD. Whether this represents a form of 'hyperacute' GVHD or an 'engraftment syndrome' remains unclear, but since steroid therapy was required, they were scored as having GVHD for the purpose of analysis. This peri-engraftment rash and fever syndrome was especially common among the URD patients, occurring in 14 of 16 patients, and is reflected in the early onset of GVHD in the URD curve in Figure 1 . Some of the patients who developed this peri-engraftment rash and fever syndrome did go on to have manifestations of acute GVHD in other organs. In total, 10 of 41 (25%) patients in this study were documented to have intestinal and/or hepatic acute GVHD.
Chronic GVHD
Chronic GVHD developed in 17 of 34 (50%) patients who survived beyond day þ 100. Of these 17 cases, seven were considered limited and 10 extensive chronic GVHD. In the MRD cohort, the incidence of chronic GVHD was 48%. In the URD cohort, chronic GVHD was 55%. The composition of the graft and its influence on acute and chronic GVHD were examined. The number of infused CD34 þ , CD4 þ , or CD8 þ cells did not significantly increase the development of chronic GVHD (data not shown).
Patient outcome
With a median follow-up of 21.6 months in surviving patients (range, 9.9-29.6 months), 1-year overall survival and event-free survival for the combined cohort are 65 and 63%, respectively, and 2-year overall and event-free survival are 56 and 57%, respectively ( Figure 2 ). There is no significant difference between the MRD and URD cohorts in overall survival (P ¼ 0.14) and event-free survival (P ¼ 0.14). At 1-year overall survival was 68% in the MRD cohort, and 63% in the URD cohort. There have only been two relapses, and both patients had extramedullary acute myelogenous leukemia. Other causes of death have included infectious pneumonitis (5) from CMV, PCP, Nocardia, Aspergillus, and Klebsiella, respectively; bacterial sepsis (3) from Pseudomonas, Staph aureus, and Corynebacteria; hepatic GVHD (3); Listeria meningitis (1); idiopathic pneumonia syndrome (1); HUS/TTP (1); and hepatic VOD (1). Only one patient developed invasive fungal infection and only three had evidence of CMV reactivation. There were no cases of symptomatic EBVrelated lymphoproliferative disease, though the one patient who died of CMV pneumonitis was found to have a focus of EBV-LPD in a lymph node at post mortem.
Immunologic recovery
The phenotypic reconstitution of MRD PBMC treated with donor CD8 þ depletion is depicted in Figure 3a .
At the one month time point, the initial mononuclear cells are primarily natural killer (NK) cells; T and B cells make up a much smaller proportion of PBMCs. CD3 þ lymphocytes increased in number over the first year after transplant. T-cell subset reconstitution seen in these patients was quite different than what has previously been reported with other forms of TCD.
19-21 CD4 þ lymphocytes steadily recovered post transplant, but the return of CD8 þ CD8 þ T-cell-depleted allogeneic PBSCT VT Ho et al lymphocytes lagged substantially behind the CD4 þ lymphocyte return. Throughout the first year, patients generally had more circulating CD4 þ cells than CD8 þ cells with a CD4/CD8 ratio greater than 1.0. CD4 þ reconstitution appeared to be driven mostly by expansion of existing cells as the vast majority of CD4 cells expressed the CD45RO marker, which is predominantly found on memory T cells, whereas the majority of CD8 cells were socalled 'naı¨ve' RA þ cells (Figure 3b ). The numbers of CD4 þ /CD25 þ lymphocytes were only measured at 1 year, by which time they had returned to levels noted in controls (data not shown).
Discussion
Using anti-CD8 antibody coated high-density microparticles, we have conducted two clinical trials investigating CD8 þ TCD as GVHD prophylaxis after filgrastim mobilized peripheral blood stem cell transplantation from MRD and URDs. Despite a 2-log reduction of CD8 þ T cells, acute GVHD control was suboptimal. Grade 2-4 acute GVHD developed in 44% in the MRD cohort and 88% in the URD cohort. It is not clear why CD8 depletion successfully reduced GVHD in our DLI studies, but not these PBSCT studies. One possible explanation is that the number of CD8 þ cells infused in these PBSC grafts were more than 3-10 times higher than the number of CD8 þ T cells (0.7 Â 10 5 CD8 cells/kg) administered to patients receiving purged DLI in our previously published randomized study in which CD8 depletion eliminated GVHD.
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The number of CD8 þ cells infused, the concomitant administration of CD34 þ cells, the use of filgrastim, or the proximate exposure to ablative conditioning may explain the difference in GVHD rates between these PBSCT and DLI studies. Even though our analyses did not reveal any statistical association between CD8 þ cell dose and outcomes, it is possible that the relationship between CD8 number and GVHD is nonlinear, and that a threshold effect exists. Therefore, it remains conceivable that greater selective reductions in CD8 þ cell numbers may result in reduced GVHD incidence. Alternatively, it is likely that GVHD is not exclusively mediated by CD8 þ T cells, and that the remaining CD4 þ T cells in the PBSC product are also important in the pathogenesis of GVHD. Graft engineering techniques that can decrease the CD8 þ T cell content of mobilized peripheral blood cells further may be helpful to resolve these questions.
Although the 2-log depletion of CD8 þ cells from PBSC in these trials was insufficient to eradicate GVHD, it may have contributed to GVHD prevention to some extent. For example, the 44% grade II-IV acute GVHD incidence observed in our CD8 þ depleted MRD cohort is actually much lower than the 70% (62% grade III-IV) reported for MRD PBSCT using tacrolimus alone without methotrexate as GVHD prophylaxis. 22 Similarly, Nimer and co-workers had reported a grade 2-4 acute GVHD incidence of 80% in the control patients of their randomized trial, who had received matched sibling BMT with cyclosporine alone as GVHD prophylaxis. 12 Several studies have suggested that donor CD8 þ cells can have potent effects in preventing marrow graft rejection. 8, 23, 24 However, in our study, CD8 þ TCD did not hinder engraftment. Indeed, in contrast to the results of most other TCD techniques, all patients tested in our series developed complete donor derived hematopoiesis. Mixed donor/recipient lymphohematopoietic chimerism is common after T-cell-depleted BMT and is a recognized risk factor for disease recurrence post transplant. 8, [23] [24] [25] [26] The durability of donor cell engraftment after CD8-depleted mobilized PBCT may be attributable to the increased number of CD34 þ hematopoietic progenitors infused compared with bone marrow. Alternatively, maintenance of the donor graft may be mediated by lymphocytes or other cells not affected by selective CD8 þ TCD. Finally, it is possible that the 2-log depletion of CD8 þ cells from PBSC in this trial left enough residual cells to support engraftment and GVHD, and issues with graft failure may yet emerge with more intensive CD8 depletion.
The estimated relapse rate of patients in this series was less than 5%. This finding is consistent with the reports of GVL preservation from studies of CD8 þ T-cell-depleted bone marrow transplantation 27 and donor lymphocyte infusion, [9] [10] [11] [27] [28] [29] and is consistent with the IBMTR retrospective report that narrow specificity TCD approaches lead to less disease relapse post transplant than broad specificity techniques. 8 However, our interpretation of relapse risk may be limited by small sample size and short follow-up duration. Larger numbers of patients with extended periods of follow-up will be necessary to confirm that partial depletion of CD8 þ cells is not associated with an increased risk of recurrent malignancy.
Despite the incidence of acute GVHD, 1-year survival rates in our CD8-depleted cohorts (65%) are comparable to those reported for non-T-cell-depleted transplant series in MRD and URD PBSCT. This may be a reflection of the fact that a vast majority of the acute GVHD cases, especially in the URD series, were periengraftment skin rashes that developed during neutrophil recovery, and were easily resolved with steroids.
The observation of a very predictable skin rash associated with fevers at or before neutrophil engraftment after CD8 TCD was one of the most striking findings in our study. A similar 'engraftment syndrome' presenting as fever, fluid overload, and mild skin rash around day þ 7 has been previously reported in patients who received immunomagnetically CD8-depleted bone marrow grafts.
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In that study, patients also responded promptly to corticosteroids, but were not scored as having skin GVHD. The finding that 16 of 41 (39%) patients in our combined cohorts developed a periengraftment rash associated with fever raises the possibility that a suppressor CD8 þ T cell population exists, and that its elimination results in an unregulated cutaneous immune response, perhaps mediated by CD4 þ cells. Cosmi and co-workers have recently identified a subset of CD8 þ CD25 þ T regulatory cells that express Foxp3 in the human thymus. 31 Whether the periengraftment rash we observed with CD8 depletion represents a form of acute GVHD, 'engraftment syndrome', or is a distinct cutaneous inflammatory process requires further investigation.
Reducing clinically significant GVHD without compromising engraftment, infectious surveillance, or antitumor activity remains the most sought after goal of allogeneic transplant research. It would be ideal if T-cell subsets that mediate GVH and GVL could be distinguished so that grafts can be engineered to minimize GVH while preserving GVL activity. Unfortunately, the distinction between GVH and GVL is not likely to be as simple as the CD4/CD8 dichotomy. 
